Overview
What it is.
Ipamorelin is a growth hormone secretagogue studied for selectively stimulating GH release without the pronounced cortisol and prolactin effects seen with earlier-generation compounds in its class — a selectivity profile that makes it one of the most widely studied secretagogues.
Research Areas
- Studied for its potential role in selective growth hormone release
- Studied for its potential role in recovery and sleep-quality research
- Studied for its potential role in body-composition research alongside diet and exercise variables
Batch & Testing
Proof, not promises.
COA ships with every order
Every batch we release is independently HPLC tested before it ever reaches a lab bench. Browse the full certificate library.
Research Deep-Dive
How it works.
Research Deep-Dive
How it works.
Ipamorelin is a pentapeptide growth hormone secretagogue developed by Novo Nordisk and derived from the older compound GHRP-1. It's best known for being the first GHRP-family compound shown to stimulate GH release without meaningfully raising cortisol or prolactin, which is why licensed programs favor it over earlier-generation peptides like GHRP-6.
Ipamorelin activates the ghrelin receptor (GHS-R1a) on the pituitary, triggering a single, sharp pulse of GH release that mimics the body's natural pattern. Unlike older GHRPs in its class, it does this with a high degree of receptor selectivity, largely sparing the ACTH/cortisol and prolactin pathways that other secretagogues also activate.
Use Cases Explored
- Studied for its potential role in selective growth hormone release with limited effect on cortisol and prolactin
- Studied for its potential role in recovery and sleep quality
- Studied for its potential role in body composition alongside diet and exercise
The Evidence
Preclinical selectivity studies (Raun et al.)
In rat and swine studies, ipamorelin released GH with potency comparable to GHRP-6, but — unlike GHRP-6 and GHRP-2 — did not meaningfully raise ACTH or cortisol, even at doses over 200 times its GH-release threshold. This selectivity finding is the core evidence behind ipamorelin's reputation, but it comes from animal models.
Small human PK/PD studies
Two published dose-escalation studies in healthy male volunteers (roughly 8 subjects per dose group) confirmed dose-proportional pharmacokinetics and a short-lived, single GH pulse peaking under an hour after dosing — real human data, but small, short-duration pharmacology studies, not outcome trials.
Discontinued Phase II trial for postoperative ileus
Ipamorelin reached a completed Phase II trial (NCT00672074) for postoperative ileus, supported by rat models showing increased GI motility, but development for that indication was discontinued without regulatory approval.
No approved product; broader wellness claims outrun the trial record
Human evidence remains limited to two small PK/PD studies and one discontinued Phase II trial. Claims about body composition, recovery, or anti-aging effects in adults are extrapolated from mechanism and the GHRH+secretagogue rationale, not from dedicated ipamorelin outcome trials.
Specifications
The essentials.
Specifications
The essentials.
- Vial Capacity
- 3 ml glass vial
- Form
- Lyophilized powder
- Solubility
- Reconstitute with bacteriostatic water
- Storage
- Store in a cool, dry place. Refrigerate at 2–8°C after reconstitution
- Shelf Life
- 24 months lyophilized; 4–6 weeks refrigerated after reconstitution
Growth Hormone
Ipamorelin
A selective growth hormone secretagogue studied for a cleaner signaling profile than older GHRPs.
Size
COA-backed guarantee — independently test any vial; if it's under 99% purity, full refund + testing costs covered.
All products sold by One Tap Peptides are intended for laboratory research use only. Not for human consumption. Not intended for animal use. Not intended for diagnostic or therapeutic purposes.
Related
